非小细胞肺癌放化疗期间辐射暴露与18F-氟胸苷正电子发射断层显像测量的骨髓功能及淋巴细胞计数之间的剂量-反应关系
26例非小细胞肺癌患者接受铂类放化疗至60 Gy/30次,期间行FLT-PET/CT扫描。累积剂量≥3 Gy的骨髓区域FLT摄取在2周时被消融,骨髓增殖在2周≥3-4 Gy和4周≥4-5 Gy后下降>95%。4周时消融骨髓百分比与淋巴细胞计数下降显著相关(R2adj=0.34,P=.001)。
要点
- 胸部放疗累积剂量≥3 Gy的骨髓区域在2周时FLT摄取被消融。
- 骨髓增殖在2周≥3-4 Gy和4周≥4-5 Gy后显著下降>95%。
- 4周时消融骨髓百分比与淋巴细胞计数下降显著相关(R2adj=0.34,P=.001)。
核心结论
- 放化疗期间低剂量辐射暴露相关的骨髓消融与4周时较低的淋巴细胞计数显著相关。
- 骨髓是潜在危及器官,减少暴露于≥3 Gy的骨髓体积可能有助于保护淋巴细胞,这对有效的辅助免疫治疗至关重要。
研究设计与样本
- 26例非小细胞肺癌患者接受铂类放化疗至60 Gy/30次,在基线、第2周(20 Gy)和第4周(40 Gy)行FLT-PET/CT扫描。
- 使用医学图像合并软件分离骨髓FLT摄取,将第2周和第4周FLT-PET骨髓扫描与同期放疗等剂量分布融合。
- 采用广义线性模型和限制性立方样条模型分析辐射剂量与骨髓FLT摄取的关系。
主要发现
- 胸部FLT摄取在累积辐射剂量≥3 Gy的骨髓区域于第2周被消融。
- 所有病例中,骨髓FLT最高标准化摄取值随辐射剂量增加而迅速下降。
- 骨髓增殖在2周≥3-4 Gy和4周≥4-5 Gy后显著下降>95%。
- 消融骨髓体积从第2周到第4周增加,因半影区骨髓累积辐射剂量。
- 消融骨髓占总骨髓的中位百分比第2周为13.1%(范围5.6%-20.3%),第4周为15.7%(范围9.2%-24.1%)。
关键数值与推荐
- 骨髓增殖显著下降>95%对应2周≥3-4 Gy和4周≥4-5 Gy。
- 消融骨髓中位百分比第2周13.1%(范围5.6%-20.3%),第4周15.7%(范围9.2%-24.1%)。
- 淋巴细胞下降与第4周消融骨髓百分比相关(y=-46至1.64x;R2adj=0.34;P=.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-fluorothymidine (FLT) positron emission tomography (PET) enables sensitive imaging of bone marrow (BM) proliferation. Sequential FLT-PET/computed tomography scans before and during chemoradiation therapy (CRT) for non-small cell lung cancer were repurposed to investigate the dose-response effects of radiation on BM proliferation. METHODS AND MATERIALS: Twenty-six non-small cell lung cancer patients underwent platinum-based CRT to 60 Gy in 30 fractions with FLT-PET/computed tomography scans at baseline, week 2 (20 Gy), and week 4 (40 Gy). FLT uptake in BM was isolated using Medical Image Merge software. Weeks 2 and 4 FLT-PET BM scans were fused with contemporaneous radiation isodose distributions. Relationships between radiation dose and FLT BM uptake (highest standardized uptake values within the volume and visual parameters) were analyzed using generalized linear and restricted cubic spline models. Percentage volumes of total BM without appreciable FLT uptake ("ablated") on weeks 2 and 4 FLT-PET scans were calculated by comparisons with baseline scans. RESULTS: Thoracic FLT uptake was ablated in BM regions exposed to cumulative radiation doses ≥3 Gy by week 2. In all cases, BM FLT's highest standardized uptake values within the volume declined rapidly as the radiation dose increased. BM proliferation significantly decreased by >95% after ≥3 to 4 Gy at 2 weeks and ≥4 to 5 Gy at 4 weeks. The ablated BM volume increased from week 2 to week 4 as BM in the penumbra accumulated radiation dose. The median percentage of total BM ablated was 13.1% (range, 5.6%-20.3%) at 2 weeks and 15.7% (range, 9.2%-24.1%) at 4 weeks. Mean lymphocyte counts fell from a baseline of 2.01 × 109/L to 0.77 at week 2 and 0.60 at week 4. Lymphocyte decline strongly correlated with the percentage of total BM ablated by week 4 (y = -46 to 1.64x; R2adj = 0.34; P = .001). CONCLUSIONS: BM ablation associated with low-dose radiation exposure during CRT correlated significantly with lower week 4 lymphocyte counts. BM is a potential organ at risk, and reducing the BM volume exposed to ≥3 Gy may help preserve lymphocytes, which is essential for effective adjuvant immunotherapy.
引用
- MacManus MP, Prins E, Xie J, et al. Dose-Response Relationships Between Radiation Exposure, Bone Marrow Function as Measured by 18F-Fluorothymidine Positron Emission Tomography, and Lymphocyte Counts During Chemoradiation for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39233020. doi:10.1016/j.ijrobp.2024.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。